Aethlon Medical, Inc. — Form 10-Q Summary
Business context and period. This unaudited Form 10-Q covers the three months ended June 30, 2019, Aethlon’s fiscal first quarter, and compares results with the three months ended June 30, 2018. Aethlon is a clinical-stage medical technology company developing the Hemopurifier for cancer and life-threatening viral infections; its majority-owned subsidiary, Exosome Sciences, pursues diagnostic biomarkers. The Hemopurifier has FDA Breakthrough Device designations for specified viral and cancer indications, but remains in development.
Financial results and condition
| Metric | Q1 FY2020 | Q1 FY2019 |
|---|---|---|
| Revenue, all government contract/grant | $30,000 | $149,625 |
| Operating expenses | $1,596,188 | $1,246,897 |
| Operating loss | $(1,566,188) | $(1,097,272) |
| Net loss attributable to Aethlon | $(2,066,424) | $(1,146,228) |
| Basic and diluted loss per share | $(0.11) | $(0.06) |
| Net cash used in operations | $(1,247,685) | $(818,431) |
- Revenue was government-contract revenue, not reported product sales. No gross margin is presented.
- Cash was $2,492,354 at June 30, 2019, down from $3,828,074 at March 31, 2019. Working capital was $846,614, versus $2,004,188 at March 31.
- Total assets were $2,932,905; total liabilities were $1,914,713. Current liabilities were $1,797,454. Convertible notes, net, were $892,591, with $11,352 accrued interest shown separately. Lease liabilities totaled $210,336.
- Cash used in investing was $886; cash used in financing was $87,149, including $100,000 of note principal payments, partly offset by $36,622 net ATM proceeds. Cash declined by $1,335,720 during the quarter.
- The filing does not report a clear margin measure. Operating and net losses substantially exceeded revenue.
Material changes and unusual items
- Revenue fell by $119,625: the prior-year melanoma contract was completed, while the current quarter included $30,000 under an NCI breast-cancer grant.
- Operating expenses rose $349,291, or 28%, primarily from higher clinical-trial and manufacturing-related costs, legal fees, laboratory supplies, and travel.
- The company reduced the convertible-note conversion price from $3.00 to $0.68 per share. This modification was accounted for as a debt extinguishment and generated a $447,011 noncash loss, materially increasing reported net loss.
- In July 2019, Aethlon paid the remaining note principal and accrued interest, totaling $903,944. It also raised $290,976 net through ATM sales of 570,006 shares in July, creating additional share dilution.
- Aethlon adopted lease accounting on April 1, 2019, recognizing a $228,694 right-of-use asset and lease liability at adoption.
- In June 2019, Aethlon entered a cross-licensing and development agreement with SeaStar Medical to co-develop the Hemopurifier cartridge and a closed-system configuration.
Outlook, risks, and contingencies
- Management stated that significant additional financing is necessary to fund operations, clinical trials, and product development. The company plans to seek capital through ATM equity sales, other equity or debt financing, and government grants. Management believed expected financing and available cash could meet needs for twelve months from filing, but gave no assurance that funds would be obtained.
- The filing states that recurring losses and the need for additional capital raise substantial doubt about Aethlon’s ability to continue as a going concern. Management expects negative cash flows and net losses to continue; no profitability or revenue guidance is provided.
- Aethlon was preparing for an early cancer clinical trial and reported active communication with FDA. Commercialization depends on clinical success, regulatory approvals, financing, and market acceptance.
- Nasdaq notified the company in May 2019 that it did not meet the $1.00 minimum bid-price requirement and in July 2019 that it did not meet the $2.5 million minimum stockholders’ equity requirement. Failure to regain and maintain compliance could result in delisting.
- The company reported no pending or threatened legal proceedings and no material off-balance-sheet arrangements. Ordinary-course claims remain a potential risk.
Important facts for investors to verify
- Whether Aethlon secures sufficient financing to support operations and planned clinical development, and whether its cash runway assumptions are achieved.
- Progress, timing, and regulatory requirements for planned Hemopurifier cancer trials and the outcome of FDA discussions.
- Whether Nasdaq listing deficiencies are cured and maintained, including bid-price and stockholders’ equity requirements.
- Terms and remaining capacity of ATM and other equity programs, subsequent share issuances, and the resulting dilution.
- Whether the SeaStar collaboration advances to a workable system and produces measurable clinical or commercial progress.
- The filing’s comparative net-loss discussion contains an apparent period-date typo; the financial statements identify the comparison as the three months ended June 30, 2018.